BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 37 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,427 | -96.4% | 97,088 | -40.3% | 0.00% | -100.0% |
Q1 2023 | $537,085 | +1828.9% | 162,753 | +858.6% | 0.00% | – |
Q4 2022 | $27,844 | -58.4% | 16,978 | -29.7% | 0.00% | – |
Q2 2022 | $67,000 | -59.4% | 24,134 | -50.8% | 0.00% | – |
Q1 2022 | $165,000 | -35.3% | 49,097 | -26.2% | 0.00% | – |
Q1 2021 | $255,000 | -45.6% | 66,512 | -35.9% | 0.00% | -100.0% |
Q4 2020 | $469,000 | +143.0% | 103,738 | +130.2% | 0.00% | 0.0% |
Q4 2019 | $193,000 | -60.9% | 45,059 | -64.4% | 0.00% | -75.0% |
Q3 2019 | $493,000 | +12.3% | 126,459 | +13.7% | 0.00% | 0.0% |
Q2 2019 | $439,000 | +116.3% | 111,245 | +137.6% | 0.00% | +100.0% |
Q1 2019 | $203,000 | +463.9% | 46,823 | +365.1% | 0.00% | – |
Q4 2018 | $36,000 | +1100.0% | 10,067 | +1577.8% | 0.00% | – |
Q2 2017 | $3,000 | -66.7% | 600 | -72.5% | 0.00% | – |
Q1 2017 | $9,000 | -18.2% | 2,180 | -43.9% | 0.00% | – |
Q4 2015 | $11,000 | +22.2% | 3,883 | 0.0% | 0.00% | – |
Q3 2015 | $9,000 | -43.8% | 3,883 | -11.4% | 0.00% | – |
Q2 2015 | $16,000 | – | 4,383 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 2,500 | $825,000 | 0.55% |
SABBY MANAGEMENT, LLC | 136,484 | $27,310 | 0.02% |
LIBERTY WEALTH MANAGEMENT LLC | 352,619 | $71 | 0.02% |
Weaver Consulting Group | 99,356 | $19,881 | 0.01% |
ABNER HERRMAN & BROCK LLC | 145,500 | $29 | 0.00% |
JMAC ENTERPRISES LLC | 65,430 | $13,093 | 0.00% |
Professional Financial Advisors, LLC | 17,279 | $3,458 | 0.00% |
Ikarian Capital, LLC | 90,242 | $18,057 | 0.00% |
MOORE CAPITAL MANAGEMENT, LP | 200,000 | $40,020 | 0.00% |
Weaver Consulting Group | 45,000 | $2,750 | 0.00% |